ArticleInternational journal of clinical oncology2026
Impact of lymph node yield on biochemical recurrence in patients with high-risk prostate cancer after robot-assisted radical prostatectomy.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundThis study evaluated the association between lymph node yield (LNY) and biochemical recurrence (BCR) after radical prostatectomy with pelvic lymph node dissection (PLND) in patients with intermediate to very high-risk prostate cancer.
methodsIn total, 1234 patients with intermediate to very high-risk prostate cancer who underwent robot-assisted radical prostatectomy between 2004 and 2025 were reviewed. Patients were compared according to the median LNY, subgroup analyses were performed according to pathological nodal status and NCCN risk classification. Propensity score was used to match the pathological factors between LND groups. BCR-free survival and its predictors were assessed using the Kaplan-Meier method and Cox proportional hazard models.
resultsAccording to NCCN classification, 18%, 49%, 25%, and 8% of patients were classified as favorable intermediate, unfavorable intermediate, high, and very high risk, respectively. The median follow-up period was 5.0 (interquartile range/IQR 2.6, 8.2) years, and 28% of patients developed BCR. The median LNY was 7 (IQR 4-11). Among patients without pN+ disease, 10-year BCR-free survival rates were 60% in those with LNY ≥ 7, compared with 48% in those with LNY < 7 (p = 0.032). This association was statistically significant only in the high-risk subgroup (p = 0.028). Race, PSA level, Gleason grade group ≥ 4, extraprostatic extension, seminal vesicle invasion, lymphovascular invasion, positive surgical margin, pN+ , and LNY ≥ 7 were independent predictors of BCR.
conclusionsHigher LNY was independently associated with improved BCR-free survival in node-negative patients undergoing limited PLND. More lymph node dissection in limited PLND may benefit selected high-risk patients.
Indexed as
Identifiers
42536276What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.